This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Forest Tennant, MD, DrPH
West Covina, Calif

Arch Intern Med. 1994;154(10):1163-1164.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recently, Fingerhood and associates¹ reported that 86% of intravenous drug users in Baltimore, Md, tested positive for antibodies to hepatitis C (HCV). Approximately one fourth of their subjects demonstrated that concentrations of the liver enzymes, aspartate aminotransferase and alanine aminotransferase, were elevated greater than two times normal. This obvious evidence of ongoing liver disease coupled with a low prevalence of hepatitis B surface antigen (4%) and human immunodeficiency virus type 1 (9%) caused Fingerhood et al to be greatly concerned about the potential for future health care costs related to HCV. They state, "in a population already using a disproportionate share of health care, HCV poses a real threat as an additional burden on limited health care resources and money." I recently helped conduct a seroprevalence study of hepatitis B and C markers in intravenous heroin addicts in California. The results were similar to those of Fingerhood et al . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?